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Abstract
Background: The aim of this study was to estimate healthcare resource utilization, work absenteeism and cost per patient with
pandemic influenza (H1N1)2009, from its beginning to March 2010, in Spain. We also estimated the economic impact on healthcare
services.
Methods and Findings: Longitudinal, descriptive, multicenter study of in- and outpatients with confirmed diagnosis of influenza A
(H1N1) in Spain. Temporal distribution of cases was comparable to that in Spain. Information of healthcare and social resources used
from one week before admission (inpatient) or index-medical visit (outpatient) until recovery was gathered. Unit cost was imputed
to utilization frequency for the monetary valuation of use. Mean cost per patient was calculated. A sensitivity analysis was
conducted, and variables correlated with cost per patient were identified. Economic impact on the healthcare system was estimated
using healthcare costs per patient and both, the reported number of confirmed and clinical cases in Spain. 172 inpatients and 224
outpatients were included. Less than 10% were over 65 years old and more than 50% had previous comorbidities. 12.8% of
inpatients were admitted to the Intensive Care Unit. Mean length of hospital stay of patients not requiring critical care was 5 days
(SD=4.4). All working-inpatients and 91.7% working-outpatients went on sick leave. On average, work absenteeism was 30.5 days
(SD=20.7) for the first ones and 9 days (SD=6.3) for the latest. Caregivers of 21.7% of inpatients and 8.5% of outpatients also had
work absenteeism during 10.7 and 4.1 days on average respectively. Mean cost was J6,236/inpatient (CI95%=1,384–14,623) and
J940/outpatient (CI95%=66–3,064). The healthcare economic burden of patients with confirmed influenza was J144,773,577
(IC95% 13,753,043–383,467,535). More than 86% of expenditures were a result of outpatients’ utilization.
Conclusion: Cost per H1N1-patient did not defer much from seasonal influenza estimates. Hospitalizations and work
absenteeism represented the highest cost per patient.
Citation: Galante M, Garin O, Sicuri E, Cots F, Garcı ´a-Alte ´s A, et al. (2012) Health Services Utilization, Work Absenteeism and Costs of Pandemic Influenza A (H1N1)
2009 in Spain: A Multicenter-Longitudinal Study. PLoS ONE 7(2): e31696. doi:10.1371/journal.pone.0031696
Editor: Benjamin J. Cowling, University of Hong Kong, Hong Kong
Received August 2, 2011; Accepted January 17, 2012; Published February 14, 2012
Copyright:  2012 Galante et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by the Instituto de Salud Carlos III (ISCIII GR09/0026). The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jalonso@imim.es
Introduction
Each year, seasonal influenza waves result in substantial
mortality and morbidity, productivity losses, increase healthcare
utilization, and costs [1–4]. Occasionally, the virus spread globally
generating the need of rapid responses from healthcare services
and public health policy makers. Such was the case of the
pandemic influenza A (H1N1) 2009. Evidence based decisions in
such circumstances are essential for the best management [5].
However, there is scarce information about social and healthcare
resource utilization and their associated costs in both epidemic and
pandemic influenza outbreaks.
Significant increases in healthcare use are expected every year
due to winter-virus morbidity [4]. Characteristics of hospital
resource utilization have been described for seasonal influenza in
the US and UK [2,6,7]. In the case of influenza A (H1N1) 2009
there exist some information of admissions to critical care services
[8]. Nevertheless, most flu cases will never be admitted to the
hospital. For instance, 744,795 confirmed influenza A (H1N1)
2009 cases in Spain were treated in the ambulatory health services,
and only 3,025 were hospitalized [9,10].
Furthermore, the most important burden of influenza is related
to productivity losses of both patients and caregivers [11–13]. The
higher incidence among children during the pandemic might have
increased the number of people who needed to be absent from
work for caregiving [14]. In fact, work leave due to flu syndrome
was even more frequent than that observed in previous seasonal
influenza outbreaks [15].
While modelling tools can be useful to anticipate the economic
impact of influenza outbreaks and their determinants, they are
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31696limited by their assumptions which concern unknown future events.
Many studies published at the beginning of the pandemic flu in 2009
have overestimated the morbiditya n dm o r t a l i t yr a t e sa n dh e n c e ,
both pandemics economic impact and the effectiveness of massive
vaccination programmes [16–18]. The alternative to simulations is
the use of empirical studies. Badia et al estimated the seasonal
economic impact of influenza in J1036.9 million in Spain more than
one decade ago [1]. However, neither has recently economic impact
been measured for seasonal influenza in Spain, nor have the cost
determinants for pandemic influenza A (H1N1) 2009.
Increasing knowledge about resource utilization and its
associated costs during the pandemic flu should facilitate decision
making and planning public health policies in future outbreaks.
The primary objective of this study was to estimate the healthcare
resource utilization, work absenteeism and cost per patient with
confirmed diagnosis of pandemic influenza A (H1N1) 2009, from
the beginning of the pandemic to march 2010, in Spain. As a
secondary objective, we estimated the economic impact of H1N1
cases on the healthcare services at a national level.
Methods
This was a multicenter, observational, longitudinal study
assessing healthcare resources utilization and work absenteeism of
inpatients and outpatients with confirmed diagnosis of influenza A
(H1N1) 2009 in Spain. We estimated the associated direct
healthcare costs and indirect costs derived from work absenteeism;
using an incidence approximation. Since flu consequences generally
occur during a short period of time, the time horizon was four
months. Hence, discount rates were not needed. Costs per patient
are presented in J (2009), and they are a function of unit costs and
the frequency of social and healthcare resource use. In addition, we
estimated the economic burden of pandemic Influenza A (H1N1) at
the overall population level from the healthcare provider’s
perspective. To achieve this objective we took into consideration
both healthcare costs per patient and the reported number of
influenza cases to the Spanish influenza Sentinel Surveillance
System (outpatients) coordinated at the National Centre of
Epidemiology (Institute of Health Carlos III) and to Surveillance
System of severe influenza cases and deaths coordinated by the
Centre for Health Alerts and Emergencies within Spanish Ministry
of Health and Social Policy (inpatients) [9,10].
Ethics Statement
This study was approved by the Parc de Salut Mar ethic review
board, and followed contemporary Spanish laws and declaration
of Helsinki. Written informed consent was obtained from all
patients. In the case of children and adults with mental disabilities,
written consent was provided by parents/guardians.
Estimating healthcare resource utilization and work
absenteeism
Healthcare resources utilization, and work absenteeism of
patients and their caregivers were directly reported by a
population of inpatients and outpatients with confirmed diagnosis
of influenza A (H1N1) 2009.
Population. Variables of interest were measured in a
subsample of patients recruited for the study ‘‘Risk factors of
influenza (H1N1) 2009 hospitalization and effectiveness of pharmaceutical
and non-pharmaceutical interventions in its prevention. A case-control study’’
[19]. Briefly, this case-control study recruited hospitalized cases
older than 6 months with confirmed influenza A (H1N1) 2009
admitted to one of the 36 participant hospitals, of seven Spanish
Autonomous Communities, for flu syndrome, respiratory failure,
septic shock or multi-organ failure (inpatient). Four control
patients, matched by the time period of diagnosis and the region
of residency were recruited for each case. One of them was a
patient who had consulted a primary care centre for flu syndrome
and had confirmed diagnosis of influenza A (H1N1) 2009, but had
not required hospitalization (outpatient). Patients with hospital-
acquired flu infection and those who did not give informed consent
for participation were excluded.
Data analysed in this manuscript was based on a convenience
subsample of inpatients and outpatients both with confirmed
diagnosis of influenza, from 24 out of the 36 centres which agree to
collaborate with the follow-up evaluation; like a nested case-series
within a case-control. The decision of including a subsample of
patients was based on the sample size estimations (see below) and
the resources available for this study. Patients belonging to this
subsample and who did not complete follow up were excluded from
the analysis. Comparisons between finally included patients and
patients of the case control study were done using Chi-square test.
Considering a sample size of 200 patients per group (inpatients
and outpatients), with a standard error of J722.3 [1], and an
alpha error of 0.05, the precision (width of the 95% confidence
interval) of the mean cost would be J200.2.
Variables and Sources of information. Information was
collected in two moments: at baseline and at follow up. Variables
measured at baseline referred to the seven days previous to
hospital admission (inpatients) or index medical visit (outpatient).
Because this study started after the beginning of the pandemic, this
information was gathered retrospectively: median time from the
index medical visit or hospital admission to information collection
was 125 days (IQR 89–166). Variables then collected included: (a)
socio-demographic (sex, age, occupation and Autonomous
Community) and clinical characteristics (e.g. presence and type
of previous comorbidities), (b) ambulatory healthcare resource
utilization such as preventive measures received (e.g. pandemic
influenza vaccination in patients recruited after 16th November
2009, when the vaccination campaign started in Spain),
medication, laboratory, imaging tests and medical visits due to
flu symptoms, (c) inpatients’ hospital information regarding unit
and length of stay, and (d) work absenteeism of patients and
caregivers and need to pay for a caregiver. At this time clinical and
hospital variables were gathered from the patient’s medical chart,
while social and ambulatory healthcare resource utilization was
obtained by a face-to-face or telephone interview.
At follow up, information about clinical evolution, additional
healthcare resources utilization and work absenteeism, occurring
after hospital discharge (inpatients) or index visit (outpatients), was
obtained through telephone interview, with a median time from
baseline of 105 days (IQR 63–166).
During both, baseline and follow up evaluations, in case of
children and adults presenting mental disabilities, a proxy was
interviewed instead.
While information on the type of medication (e.g. antibiotics,
antipyretics) and days of treatment was collected, the specific drug
and dose were not available. We assumed utilization rates in
accordance with recommendations from local Clinical Practice
Guidelines, for adults and children separately [20,21].
Social class was defined based on occupation and according to
the Spanish Society of Epidemiology classification. Categories
were then grouped into manual (classes IV y V) and non manual
(classes I, II and III) [22].
Estimating unit costs
The Spanish National Health System does not have information
of unit costs. Hence, alternative available sources were considered
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describes the unit costs used in this study as well as the sources of
information. Unit costs of ambulatory healthcare resources
considered included: (a)the reimbursement tariff available at the
public price lists of the official bulletins of Catalonia [23] and
Madrid [24] [24]; (b)the retail price of medicines published at a
Spanish vademecum [25]; (c)the actual costs of diagnostic tests
calculated from the price list of the Hospital Clinic of Barcelona;
and (d)the mass media publications of the pandemic vaccine price
[26]. The cost per day of hospitalization was calculated in 77
patients (not necessarily included in this study) admitted for
influenza A (H1N1) (ICD-9 488.1) to one of the participant
hospitals (Hospital del Mar) during the same study period. This
hospital has a clinical costing system that allows establishing
hospital expenses according to hospitalization unit [27]. The cost
per day at the Intensive Care Unit (ICU) and the general ward was
calculated separately dividing the total expenses by the total days
of hospitalization in each unit.
The cost per working day was obtained from the National
Statistics Institute (INE), and was specific for each Autonomous
Community on the fourth quarter of 2009 [28].
Analysis
Descriptive analysis was done to characterize the study
population. The number and percentage of patients that used
each healthcare and incurred in work absenteeism was informed.
Table 1. Unit costs of healthcare and social
1 resources: sources of information and calculation method.
Resource Unit Cost (J) Source
Primary care GP’s visit
2 37.5 DOGC, BOMA
Primary care ED visit
3 87.7 DOGC
Home medical care visit
3 58.5 DOGC
Occupational care visit
3 100 Expert
Hospital ED visit
2 139.6 DOGC, BOMA
Outpatient office visit (adults)
2 167.3 BOMA
Outpatient office visit (children)
2 217.3 BOMA
Pandemic influenza vaccine
2 9.7 Mass media
Seasonal vaccine
c 11.16 Vademecum
Oseltamivir (day of treatment for adults)
4 6.514 Vademecum
Oseltamivir (day of treatment for children)
4 3.478 Vademecum
Antibiotics (day of treatment)
4 1.61 Vademecum
Oral glucocorticoids (day of treatment)
4 0.62 Vademecum
Ibuprophen-acetaminophen (day of treatment)
4 0.35 Vademecum
Chest Radiography (front and side views)
5 21.3 H. Clinic
CT without contrast
5 120.2 H. Clinic
Laboratory test
5 9.6 H. Clinic
Cost per day of hospitalization in the ICU
6 1342.3 PSMar
Cost per day of hospitalization in the in GW of ICU-inpatients
6 419.7 PSMar
Cost per day of hospitalization in the in GW of general-ward inpatients (children)
6 630 PSMar
Cost per day of hospitalization in the in GW of general-ward inpatients (adults)
6 505.2 PSMar
Cost per working day - Andalusia
3 129.2 INE
Cost per working day - Catalonia
3 134 INE
Cost per working day - Madrid
3 137.6 INE
Cost per working day – Community of Valencia
3 133.1 INE
Cost per working day - Castilla y Leon
3 129.4 INE
Cost per working day – Basque Country
3 127.9 INE
Cost per working day - Navarre
3 127.7 INE
GP: General Practitioner; ED: Emergency Department; CT: Computed Tomography; ICU: Intensive Care Unit; GW: General Ward; DOGC: Diari Oficial Generalitat de
Catalunya (Departament de Salut, Resolucio ´n SLT/383/2009); BoMA: Boletı ´n Oficial de Madrid (Conserjeria de Salud y Consumo), Order 629/2009); Expert: expert in
occupational health; Mass media: pandemic vaccine prices published in ‘‘El Paı ´s’’ newspaper available at http://www.elpais.com/articulo/sociedad/Francia/vende/
excedente/vacunas/gripe/elpepusoc/20100104elpepisoc_4/Tes Vademecum: Vademecum.es. CMP Medicom Editorial, S.A.; H. Clinic: price list of the Hospital Clı ´nic de
Barcelona; PSMar: clinical costing system of Parc de Salut Mar. INE: National Institute of Statistics.
1Social resources analysed in this study included work absenteeism of patients and caregivers and paid-caregiver requirement.
Methods for unit cost calculation:
2Mean cost of available information.
3Published cost, price or reimbursement tariff.
4Mean of Recommended Retail Price of the different brands available.
5Actual cost calculated from price lists applying the correspondent discount.
6Mean costs per day of hospitalization of inpatients with pandemic influenza A (H1N1) admitted to the Hospital del Mar during the same period.
doi:10.1371/journal.pone.0031696.t001
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calculated among users. Patients’ work absenteeism was estimated
among those who were working when the disease started.
Direct costs associated to healthcare resource utilization and
indirect costs associated to work absenteeism of patients and
caregivers (income losses) were estimated by multiplying frequen-
cy of use by each unit cost. Mean cost due to each type of
resource utilization was calculated among all patients. Pie charts
were created to show direct healthcare and indirect costs’
distribution in inpatients admitted to de ICU (ICU inpatients),
inpatients hospitalized exclusively at the general ward (general-
ward inpatients), and outpatients. Comparisons of cost per
patient between age groups were performed using Kruskal-Wallis
test.
All analyses were performed stratifying by inpatients and
outpatients.
Sensitivity analysis. Mean and 95%CI for direct healthcare,
work absenteeism and total costs per patient were estimated by a
multivariate probabilistic sensitivity analysis using Monte Carlo
simulation. Analysis was performed separately for outpatients,
ICU inpatients, general-ward inpatients and all inpatients. Input
variables distribution and parameters were estimated by fitting
distribution to data (table 2). For the probability distribution of
unit costs we considered the available published information
mentioned in the unit cost section. Frequency of healthcare
utilization and work absenteeism probabilities were based on the
observed distribution in our study population. We used a Chi-
square test to compare the observed data in our data-set with the
Table 2. Statistical characteristics of the input variables included at the multivariate probabilistic sensitivity analysis.
Distribution of inputs
Unit Cost Utilization Frequency
Outpatient Inpatient General ward patient ICU patient
Medical visits
Primary care GP’s office Uniform (36–39) Poisson (1.6652) Negative binomial
(2-0.60777)
Negative binomial
(2-0.59519)
Geometric (0.54054)
Home medical care
1 58.5J Binomial (1-0.013453) Geometric (0.80374) Poisson (0.10294) Binomial (1-0.15)
Occupational care
1 100J Binomial (1-0.079545) Binomial (1-0.017442) Binomial (1-0.0073529) Geometric (0.62329)
Hospital ED Uniform (118.9–174.6) Poisson (0.44643) Geometric (0.72269) Geometric (0.71958) Poisson (0.15)
Primary care ED
1 87.7J Geometric (0.92946) Geometric (0.80751) Geometric (0.77273)
Outpatient office Uniform (94–251) Binomial (1-0.022523) Geometric (0.68526) Geometric (0.69036) Geometric (0.8)
Medication
Antiviral agents 6.5 (adults), 3.5 (children) Binomial (1-0.30952) Geometric (0.27636) Geometric (0.25207) Geometric (0.47222)
Antipyretics
1 0.35J Geometric (0.39051) Geometric (0.21287) Geometric (0.21053) Geometric (0.22472)
Antibiotics
1 1.61J Negative binomial
(1-0.35484)
Negative binomial
(1-0.23465)
Geometric (0.23735) Geometric (0.21739)
Glucocorticoids
1 0.62J Geometric (0.94872) Geometric (0.38826) Geometric (0.40356) Geometric (0.26667)
Vaccines
Pandemic influenza (H1N1) 2009 Uniform (9.34–10) Binomial (1-0.026786) Binomial (1-0.11047) Binomial (1-0.10294) Binomial (1-0.15)
Seasonal influenza
1 11.2J Binomial (1-0.27232) Binomial (1-0.36628) Binomial (1-0.36029) Binomial (1-0.35)
Diagnosis Tests
Radiography
1 21.3J Binomial (4-0.064103) Geometric (0.67143) Poisson (0.44737) Binomial (1-0.4)
Computed Tomography
1 120.2J Binomial (1-0.010101) Geometric (0.90476) Poisson (0.064935)
Laboratory
1 9.6J Binomial (2-0.13452) Geometric (0.73438) Geometric (0.73786) Binomial (1-0.2)
Hospitalization (day)
Intensive Care Unit Uniform (1209.9–1497.81) Geometric (0.4984) Poisson (7.85)
General Ward Beta General (0.89803-
2.1841-330.79-1102.29)
Negative binomial
(3-0.34978)
Poisson (4.9926) Poisson (9.6)
Work Absenteeism (day)
Patients Uniform (126.05–139.25) Geometric (0.15581) Geometric (0.10935) Geometric (0.11175) Geometric (0.11801)
Caregivers Uniform (126.05–139.25) Geometric (0.74172) Geometric (0.29706) Geometric (0.41159) Geometric (0.11801)
Paid caregiver (day) Uniform (126.05–139.25) Poisson (0.066964) Poisson (0.098214) Poisson (0.066964)
GP: general practitioner; ED: emergency department.
Geometric distribution parameter: p (probability of success in each trial).
Uniform distribution parameters: minimum, maximum.
Negative Binomial parameters: s - p (s=mean number of successes, p=probability of success in each trial).
Binomial parameters: n - p (n=number of trials, p=probability of success in each trial).
Beta General Distribution parameters: alpha1- alpha2 – minimum - maximum (alpha1 and alpha 2=shape parameters).
Poisson parameter: l (l=mean number of success).
1no variability was introduced to these inputs due to lack of alternative unit cost information availability.
doi:10.1371/journal.pone.0031696.t002
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distributions with the lowest Chi- squared value were chosen.
The main factors affecting cost per patient were identified in the
estimated model by calculating Spearman’s rank correlation
coefficients as a measure of the magnitude of the association
between each variable and the outcome.
The @Risk 5.0. add-in tool to Microsoft Excel was used for the
sensitivityanalysis,(Palisade Corporation,Ithaca,NY,SA);and SPSS
13.0 for the rest of the analyses(SPSS, Inc., Chicago, IL, USA).
Estimating the healthcare economic burden of patients
with influenza A (H1N1) 2009 in Spain. To estimate the
healthcare economic burden generated by patients with pandemic
influenza A (H1N1) 2009, we considered the mean healthcare-cost
per patient obtained in the sensitivity analysis for each type of
patient and the number cases reported in Spain. The results of
ICU inpatients and general-ward inpatients were estimated
separately and then summed up to obtained the inpatients’
overall impact. At a national level, 852 and 2,173 inpatients with
confirmed diagnosis of influenza were attended at ICU and
general-ward, respectively [10]. Government institutions also
estimated a total of 744,795 confirmed outpatients among the
1,414,000 estimated clinical cases [9]. We informed the economic
impact on healthcare system for both, estimated confirmed and
clinical cases.
Results
One hundred seventy two inpatients and 224 outpatients were
included in the study. Neither groups differed statistically from
those of the case control study, regarding the distribution of sex
(p=0.91), age group (p=0.13) and employment before flu
(p=0.33) (figure 1).
Temporal distribution of cases included in our study was
comparable to that reported in Spain. First circulation of the virus
was detected in Spain on week 21/2009 (April 24th to May 30th)
and the beginning of pandemic wave on week 40 (October 4th to
10th). The first patient included in the study was recruited on
August 1st. Peak activity was observed on week 46/2009 in both,
Spanish surveillance system and our study [9].
Patient’s characteristics are presented in table 3. Mean age of
both groups was below 25, and less than 10% were over 65 years
old. Sixty four percent of inpatients and the 50.3% of outpatients
had some previous comorbidity. Most patients were in working
age (61% and 73.7% for inpatients, and outpatients, respectively).
Of those, 43.8% of inpatients and 66.1% of outpatients were
currently working. Pandemic vaccine was applied to 24.7%
inpatients and 8% of outpatients recruited after 16
th November
2009.
Utilization of healthcare and social resources is shown in
table 4. The mean (SD) frequency of use of each resource is
described exclusively among users. Before admission, inpatients
tended to seek medical assistance at the primary care general
practitioner’s office (43%) or at the hospital emergency depart-
ment (22.7%); while, after discharge, they were also frequently
assisted at the hospital outpatient office (23.8%). Almost twenty
percent (18.6%) of inpatients received ambulatory treatment with
antiviral drugs before hospitalization. In addition, 39.5% were
treated with antibiotics at that time. Twenty inpatients (12.8%)
required hospitalization at the ICU. The total hospital length of
stay was 17.4 days (SD=9.2) for these patients, while general-
ward inpatients were hospitalized for 5 days on average
(SD=4.4).
More than 90% of the patients in the labour force had to be
absent from work due to the flu. Mean number of lost working
days was 30.5 for inpatients and 9 for outpatients. Almost nine
percent (8.5%) of outpatients needed a caregiver who had to
interrupt work. This percentage ascended to 21.7% in the case of
inpatients.
Table 5 shows direct healthcare, indirect and total costs per
patient. For inpatients, direct costs associated to ambulatory
healthcare utilization and indirect costs derived from work
absenteeism were estimated among 172 patients. However,
hospital and total costs could only be calculated among 156
patients that had complete information of length of hospital stay.
The total mean cost was J6,028 per inpatient and J749.2 per
outpatient. Medical visits accounted for the majority of ambula-
tory costs in both groups of patients. The mean cost for
hospitalization was J4,438.5. Inpatients’ mean direct healthcare
cost (J4,687.5) exceeded mean indirect cost (J1,383). The
opposite was observed in the case of outpatients (indirect
costs=J582, direct healthcare costs=J167.3).
Figure 1. Sample selection flow chart.
doi:10.1371/journal.pone.0031696.g001
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inpatient’s cost was observed in individuals over 65 years old
(J7,985 —SD=10,979), comparing with the younger groups: #4
years: J5026 (SD=3,996), 5 to 16 years: J3,736 (SD=4,685), 17
to 64 years: J6664 (SD=6,059) (p=0.014). By contrast, cost per
outpatient was highest among patients in working age (J944 —
SD=947). Mean cost per outpatient of other age groups were
estimated as follows: #4 years: J 308 (SD=416), 5 to 16 years:
J150 (SD=128), $65 years: J273 (SD=178) (p,0.001).
Almost 90% of total cost per ICU-inpatient was explained by
hospital related costs. Indirect costs for these patients accounted
for 9% of total costs. By contrast, the proportion of indirect cost
for general-ward inpatients was 30%. This percentage ascended to
77% in the case of outpatients (figure 2).
Sensitivity Analysis
Estimates of mean cost and their intervals obtained by the
sensitivity analysis varied significantly across patients groups
Table 3. Patients’ characteristics.
Inpatients Outpatients
n=172 n=224
n( % ) n( % )
Sex
Female 88 (51.2%) 131 (58.5%)
Male 84 (48.8%) 93 (41.5%)
Age, mean (SD) 23.3 (1.8) 19.5 (1.3)
#4 21 (12.2%) 20 (8.9%)
5–16 30 (17.4%) 28 (12.5%)
17–64 105 (61%) 165 (73.7%)
$65 16 (9.3%) 11 (4.9%)
Autonomous Community
Andalusia 39 (22.7%) 14 (6.3%)
Castile and Leo ´n 1 (0.6%) 0 (0%)
Catalonia 56 (32.6%) 60 (26.8%)
Basque Country 47 (27.3%) 72 (32.1%)
Madrid 14 (8.1%) 70 (31.3%)
Valencian Community 6 (3.5%) 0 (0%)
Foral Community of Navarre 9 (5.2%) 8 (3.6%)
Employment before flu in adults in working age 46/105 (43.8%) 109/165 (66.1%)
Missing values 1( 0 . 6 %)
Social Class
Non-manual workers 72 (41.9%) 145 (64.7%)
Manual workers 51 (29.7%) 48 (21.4%)
Missing values 49 (28.5%) 31 (13.8%)
Comorbidities
Any comorbidity 110 (64%) 113 (50.3%)
Respiratory 57 (33.1%) 54 (24.1%)
Neuromuscular 21 (12.2%) 7 (3.1%)
Cardiovascular 47 (27.3%) 27 (12.1%)
Diabetes or obesity 36 (20.9%) 31 (13.8%)
Immunosuppressive condition 28 (16.3%) 20 (8.9%)
Chronic Renal Failure 11 (6.4%) 8 (3.6%)
Rheumatologic 1 (0.6%) 7 (3.1%)
Pregnancy in women in childbearing age 9/46 (19.6%) 31/88 (35.2%)
Missing values 2 (4.4%)7 ( 8 %)
Pandemic influenza H1N1 vaccination
1 19 (24.7%) 6 (8%)
Seasonal influenza vaccination 63 (36.6%) 61 (27.2%)
Social isolation measures 6 (3.4%) 4 (1.7%)
Preventive mask use 53 (30.8%) 89 (39.7%)
1Among 77 inpatients and 75 outpatients who we recruited after the pandemic (H1N1) 2009 vaccine was available in Spain (16
th November 2009).
doi:10.1371/journal.pone.0031696.t003
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14,623). Among these, cost was greatest for those needing care at
the ICU (Mean=J18,095, 95%CI 9,634–28,333), while mean
cost per general-ward inpatient was J4,288 (95%CI 1,430–8,957).
For outpatients, mean cost was J940 (95%CI 66–3,064).
The sensitivity analysis also identified the variables in the model
to which the estimates were most sensitive (figure 4). For
inpatients, the most correlated variables with total mean cost was
(1) the length of stay at the general ward (r=0.64), (2) the length of
stay at the ICU (r=0.53), and (3) the length of patient’s work
Table 4. Utilization estimators of healthcare and social
1 resources among users.
Inpatients Outpatients
n=172 n=224
Before admission After discharge Total
Patients
Use
frequency Patients
Use
frequency Patients
Use
frequency Patients Use frequency
n (%) Mean (SD) n (%) Mean (SD) n (%) Mean (SD) n (%) Mean (SD)
Medical Visits (number of
visits)
Primary care GP’s office 74 (43%) 1.5 (0.9) 63 (36.6%) 1.7 (1) 104 (60.5%) 2.1 (1.3) 224 (100%) 1.7 (1.3)
Home medical care 15 (8.7%) 1.1 (0.4) 3 (1.7%) 8.3 (7) 17 (9.9%) 2.5 (4) 3 (1.3%) 1 (0)
Occupational care 2 (1.2%) 1 (0) 1 (0.6%) 1 (0) 3 (1.7%) 1 (0) 14 (6.3%) 1 (0)
Hospital ED (without
admission)
39 (22.7%) 1.3 (0.5) 7 (4.1%) 2 (1) 45 (26.2%) 1.5 (0.9) 85 (37.9%) 1.2 (1)
Primary care ED 24 (14%) 1.5 (0.7) 3 (1.7%) 2 (1.7) 26 (15.1%) 1.6 (1.1) 12 (5.4%) 1.4 (1.2)
Outpatient office 5 (2.9%) 1.2 (0.4) 41 (23.8%) 1.8 (1.2) 44 (25.6%) 1.8 (1.2) 6 (2.7%) 1 (0)
Ambulatory medication
(days of treatment)
Antiviral agents 32 (18.6%) 4.6 (1.8) 52 (30.2%) 5.2 (3.4) 70 (40.7%) 5.7 (4) 58 (25.9%) 5.7 (1.4)
Antipyretics 130 (75.6%) 2.8 (2.8) 42 (24.4%) 7 (4.6) 134 (77.9%) 4.7 (4.4) 192 (87.5%) 5.8 (4)
Antibiotics 68 (39.5%) 3 (3.1) 51 (29.7%) 7.4 (4.6) 87 (50.6%) 6.4 (4.9) 46 (20.5%) 8.7(2.8)
Glucocorticoid 37 (21.5%) 3.1 (4.4) 14 (8.1%) 11 (14.3) 45 (26.2%) 6 (10) 2 (0.9%) 6 (0)
Vaccines (doses)
Pandemic influenza A
(H1N1)
2
19 (24.7%) 1 (0) 19 (24.7%) 1 (0) 6 (8%) 1 (0)
Seasonal influenza 63 (36.6%) 1 (0) 63 (36.6%) 1 (0) 61 (27.1%) 1 (0)
Ambulatory diagnosis tests
(number of tests)
Radiography 32 (18.6%) 1.4 (1) 32 (18.6%) 1.4 (1) 47 (21%) 1.1 (0.3)
Tomography 6 (3.5%) 1.7 (0.8) 6 (3.5%) 1.7 (0.8) 2 (0.9%) 1 (0)
Laboratory 21 (54.7%) 1.6 (0.9) 21 (54.7%) 1.6 (0.9) 52 (23.2%) 1 (0.2)
Hospitalization (days)
Hospitalization at ICU 20 (12.8%) 7.8 (3.7)
Hospitalization at GW of ICU-
inpatients
20 (12.8%) 9.6 (7.7)
Hospitalization at GW of
general-ward inpatients
136 (87.2%) 5 (4.4)
Work absenteeism (days)
Absenteeism in working
patients
46/46 (100%) 30.5 (20.7) 100/109 (91.7%) 9 (6.3)
Patients whose caregivers
required work absenteeism
38/172 (21.7%) 10.7 (14.1) 19/224 (8.5%) 4.1 (4.1)
Patients who paid for a
caregiver (days)
3/172 (3%) 5.5 (5.8) 1/224 (0.4%) 15 (0)
GP: general practitioner, ED: emergency department; ICU: Intensive Care Unit; GW: General Ward.
Missing value range: Medical visits=0 to 17, Medication=0 to 19, Missing value: hospitalization=16.
1Social resources analysed in this study included work absenteeism of patients and caregivers and paid caregiver.
2Among 77 inpatients and 75 outpatients who we recruited after the pandemic (H1N1) 2009 vaccine was available in Spain (16
th November 2009).
doi:10.1371/journal.pone.0031696.t004
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was mostly correlated to length of patient’s absenteeism (r=0.95).
Healthcare economic burden of patients with influenza A
(H1N1) 2009 in Spain
Considering the number of confirmed pandemic influenza A
(H1N1) 2009 cases in Spain and the results of healthcare cost per
patient obtained in the sensitivity analysis, the economic impact on
the health services in Spain was J144,773,577 (95%CI
13,753,043–383,467,535). Up to 86% of this cost was be
generated by outpatients, while the remaining 14% would be
attributable to inpatients’ utilization. Assuming that mean costs
associated to clinical (non-confirmed) flu cases were similar to
those of patients with confirmed diagnosis of influenza A (H1N1),
the social economic burden was estimated in J256,530,812,
(95%CI 18,437,478–694,647,860).
Discussion
Based on primary data of patients with confirmed diagnosis of
2009 pandemic influenza A (H1N1) 2009, we have estimated the
pattern of healthcare resources utilization as well as patient and
caregiver work absenteeism. Derivate cost per patient and the
economic impact on healthcare services were described. Mean
length of hospital stay was almost fourfold for patients requiring
critical care (ICU) than for patients treated at the general ward
only. As expected, inpatients needed more time to recover and
their mean length of work sick leave was 30.5 days, in comparison
with the 9 days observed for outpatients. Loss of productivity was
also important for caregivers, since 21.7% and 8.5% of inpatients
and outpatients respectively had caregivers who had to be absent
from work. From an economic point of view, at an individual level,
inpatients had a greater cost (J 6,236 per inpatient) than
outpatients (J 940 per outpatient). From the healthcare provider’s
perspective, the 86% of economic national burden was the result
of outpatients’ resource utilization. The healthcare economic
burden of patients with confirmed diagnosis of influenza A (H1N1)
Table 5. Direct healthcare and indirect costs per patient.
Cost per
Inpatient Cost per Outpatient
n=172 n=224
Mean (SD) Mean (SD)
DIRECT HEALTHCARE COST
Ambulatory resources
Medical visits 218.9 (241.5) 142.1 (133.8)
Medication 21 (25.8) 13.8 (17.9)
Vaccines 5.2 (7.1) 3.3 (5.3)
Diagnosis tests 14.6 (54.1) 8.1 (17.9)
Hospitalization
1
ICU 1181.3 (3451.6)
General ward 3257.2 (3057.7)
INDIRECT COST
2
Patient absenteeism 1068.6 (2267.1) 534 (814.3)
Caregiver absenteeism 311.7 (1044.8) 45.7 (211)
TOTAL COST
Direct healthcare cost
Ambulatory cost 259.7 (273.9) 167.3 (148)
Hospital cost
1 4438.5 (5714.8)
Total direct cost
1 4687.5 (5729.3) 167.3 (148)
Indirect cost
2 1383 (2421.2) 582 (852.8)
Total cost
1 6028 (6250.8) 749.2 (885.8)
ICU: Intensive Care Unit.
1Inpatients hospital and total costs were estimated over 156 inpatients with
complete information about length of stay.
2Indirect cost is derived from work absenteeism of patient and caregiver and
paid-caregiver requirement.
doi:10.1371/journal.pone.0031696.t005
Figure 2. Direct healthcare and indirect
1 costs’ distribution
according to patient’s group.
1Indirect cost is derived from work
absenteeism of patient and caregiver and paid caregiver. A. Inpatients
admitted to the intensive care unit at any time of the hospitalization.
(n=20). B. Inpatients hospitalized exclusively at the general ward.
(n=136). C. Outpatients. (n=224).
doi:10.1371/journal.pone.0031696.g002
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doi:10.1371/journal.pone.0031696.g003
Figure 4. Correlation of cost per patient and the main input variables (Spearman’s rank). A. Inpatients. B. Outpatient. Abbreviations: GW:
General Ward, ICU: Intensive Care Unit, GP: General Practitioner, ED: Emergency Department.
doi:10.1371/journal.pone.0031696.g004
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considering clinical cases.
The description of healthcare utilization is essential for the
healthcare provider’s administration, the economic evaluation of
health technologies and the estimation of the burden of a disease.
In agreement with previous studies, length of hospital stay of
general-ward inpatients doubled that observed for seasonal flu
[6,10]. It has been described that the risk of serious complications
was not elevated in patients with pandemic influenza (H1N1) 2009
compared with recent seasonal strains [29]. Thus, longer
hospitalizations might be attributed to differences in medical
practice during a pandemic outbreak when clinical evolution was
uncertain.
Regarding ambulatory healthcare, several economic evaluation
studies have included in their models evidence of previous seasonal
surges or from patients with influenza-like illness [30,31]. Our
study adds a detailed description of ambulatory healthcare
resource utilization, including less frequently used medical
assistance (such as home medical visits or occupational care visits)
also relevant for the health services organization.
As in previous studies of seasonal influenza, antibiotics were
more frequently used than antiviral drugs outside the hospital [32].
Since influenza is a viral infection, the antibiotic prescription was
probably inappropriate in most cases. Nevertheless, neither has the
existing evidence demonstrated a clear benefit of antiviral drugs in
reducing influenza complications [33,34].
Productivity losses represented the most important impact of the
pandemic outbreak. Compared with estimations for seasonal
influenza, length of work sick leave was almost ten times higher in
the case of inpatients, and at least two times higher in the case of
outpatients [11,35]. Moreover, length of work absenteeism during
the pandemic in Spain exceeded that reported in other European
countries [36]. This was not an exclusive feature of the pandemic
influenza A (H1N1), since it was also observed in other pathologies
[37].
Costs per patient derived from our study did not differ much
from previous estimates for seasonal influenza in our country. If
we consider that 99.8% of clinical cases were outpatients, 0.15%
were general-ward inpatients and 0.06% were ICU-inpatients, the
mean cost per pandemic influenza A (H1N1) patient in Spain
would be J954 [9,10]. In the same country, Badia et al. calculated
the mean cost per patient with seasonal influenza-like illness to be
J542.1 (95%CI=487.1–597.1). This cost and their reported cost
due to work leave resembled our results, considering that their
study was conducted one decade ago [1]. Also, our estimated
direct costs per pandemic inpatient were also similar to those
reported for seasonal influenza in the US, which ranged from US$
2,785 and US$ 13,159 [2,6,7,38].
The economic burden of health services estimated here was
considerably low in comparison with previous reports for seasonal
influenza in the United States [13,38]. Molinari et al estimated
the direct costs of the annual medical treatment for influenza in
U$S 10.4 billion. Although they considered also non-medically
attended cases, the cost of these patients accounted for less than
1% of the medical expenditures. In contrast to our results, they
calculated that 52% of the expenditures on influenza were
attributable to hospitalizations [13]. These differences might be
due to the mildness of the influenza H1N1 pandemic, the higher
cost per patient considered in their analysis and the methodology
used. Another study that included only hospital and emergency
costs, estimated the annual cost burden at $44 to $163 million
[38]. Also, costs of pandemic influenza A (H1N1) 2009 were
clearly lower than direct medical costs associated to other
pathologies in Spain, such as metabolic syndrome (J1,900
million) and knee and hip osteoarthritis costs (J4,075 million)
[39,40].
Limitations
The results of this study should be interpreted taking into
account several limitations. First, the study population was a
subsample of patients recruited for a case-control study. This is
important for outpatients who were selected to be matched with
inpatient rather than a representative sample of the outpatient
Spanish population. Therefore, external validity could be
compromised. However, patient’s were temporally representative
of the pandemic surge in Spain [9], and the prevalence of
comorbidities among our inpatient’s was similar to that reported
before [10,41]. Also, although follow-up response was not 100%,
demographic characteristics of lost patients and those who stayed
in the study were not statistically different. Second, none of the
patients included died during the influenza infection. Consequent-
ly, our estimates underestimate the actual impact of the pandemic.
Nevertheless, most patients who died during the pandemic were
either old or had previous severe chronic conditions, thus not
affecting much our estimation of indirect costs [10,41]. Third, we
could only analyse flu cases that had contact with health services
and were laboratory confirmed. This might have prevented us
from overestimating costs due to over diagnosis of influenza.
However, it could have lead us underestimate productivity costs
among specific populations (housekeepers, or non-contracted
individuals, for instance) [42]. Fourth, even though there is
evidence regarding possible differences in mean cost by social class
[12], comparisons stratifying by this variable could not be
performed due to many missing values. Also, we need to indicate
that the number of cases that were used to estimate the costs per
ICU-inpatient was small (n=20). Finally, the limitations related
with the sources of data used in our study deserve a comment.
Although some of the information was directly gathered from the
patient during an interview (to patients or proxies) and in some
cases several months after the flu, memory bias was probably
minor due to the influenza pandemic’s important mass media
repercussion [43]. We had to consider alternative sources of
information for unit costs, as there is no accepted common
information source for the Spanish national healthcare system.
While the source of unit costs for hospital and day absenteeism
were reliable, many ambulatory unit costs were probable
overestimated because they were obtained from the list of prices
of health services provision to third parties. It is worth mentioning
that several of the limitations listed above were addressed by the
sensitivity analyses performed, because variations in unit costs,
hospitalization length of stay in each area and days of work
absenteeism were introduced as inputs of the model. The resulting
confidence intervals of estimates represent the degree of
uncertainty introduced by these limitations.
In conclusion, this paper provides information for health service
providers and society during the pandemic influenza A (H1N1)
2009 which might be of interest for sizing the costs and needs of
care in such episode, and in future outbreaks of similar
epidemiological characteristics. Work absenteeism of patients
and caregivers accounted for the majority of costs per outpatient.
Interventions such as home-care provided by health services
should be explored to reduce parents’ and other relatives’
productivity losses. Clinical Practice Guidelines for general
practitioners might reduce economic impact on health services
by minimizing unnecessary health resource utilization in a
pandemic scenario. In addition, the evidence given by this study,
together with other global expenses, such as prevention cam-
paigns, massive vaccine purchase and other economy costs of
Resource Use and Costs of Pandemic Influenza A
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impact of the pandemics.
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